Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cybelle Pfeifer

Internal Medicine Lexington, KY Medical Doctor

NPI 1841428554 CMS profile 842617

University Of Kentucky 800 Rose St, Lexington, KY 40536

Open in the dashboard

General payments

$7,012

197 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cybelle Pfeifer of Lexington, KY is reported in the CMS Open Payments database as having received $7,012 across 197 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,131 46
2024 General $766 39
2023 General $2,161 40
2022 General $687 24
2021 General $272 13
2020 General $100 1
2019 General $1,896 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cybelle Pfeifer
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Cybelle Pfeifer were reported at $1,131. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Cybelle Pfeifer Internal Medicine median Middle half National median
2019 $1,896 $159 $48–$570 $163
2020 $100 $119 $33–$402 $114
2021 $272 $135 $37–$521 $132
2022 $687 $141 $42–$496 $149
2023 $2,161 $149 $45–$519 $160
2024 $766 $154 $47–$537 $164
2025 $1,131 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $1,545 5 payments
  2. Veran Medical Technologies, Inc. $1,363 5 payments
  3. Jazz Pharmaceuticals Inc. $448 18 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $398 19 payments
  5. GlaxoSmithKline, LLC. $380 14 payments
  6. Genzyme Corporation $297 14 payments
  7. Regeneron Healthcare Solutions, Inc. $291 15 payments
  8. AstraZeneca Pharmaceuticals LP $281 12 payments
  9. Electromed, Inc. $250 22 payments
  10. Ethicon Inc. $221 3 payments
  11. Other $1,540 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,582 191 payments
  2. Travel and Lodging $2,351 5 payments
  3. Education $79 1 payment
Products named General payments · program years 2019–2025
  1. NA $1,545 5 payments
  2. Spin $1,363 5 payments
  3. XYWAV $395 15 payments
  4. DUPIXENT Immunology $360 14 payments
  5. OFEV $344 15 payments
  6. DUPIXENT Inflammation And Immunology $253 13 payments
  7. SMARTVEST $250 22 payments
  8. Monarch Platform $221 3 payments
  9. YUPELRI $220 13 payments
  10. NUCALA $217 10 payments
  11. Other $2,305 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,469

Median for Pulmonary Disease: 936

Drug cost

$602,782

Median for Pulmonary Disease: $487,987

Branded share of claims

59.4%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 18 $231,123
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 220 $167,751
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 82 $50,686
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 87 $47,026
Breo Ellipta Fluticasone/Vilanterol Brand 43 $24,904
Eliquis Apixaban Brand 14 $10,838
Breyna Budesonide/Formoterol Fumarate Brand 55 $10,267
Spiriva Handihaler Tiotropium Bromide Brand 19 $9,726
Symbicort Budesonide/Formoterol Fumarate Brand 28 $9,621
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 16 $8,664

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$125,309

Medicare's payments for the services billed

Medicare patients

440

Average age 74

Services billed

1,211

242 women, 198 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 50%
Diabetes 48%
Arthritis 48%
Heart failure 45%
Chronic kidney disease 45%
COPD 43%
Atrial fibrillation 40%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • SANOFI-AVENTIS U.S. LLC $79
  • GENZYME CORPORATION $77
  • Regeneron Healthcare Solutions, Inc. $35
$192 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $115
$115 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $111
$111 18 —
YUPELRI
  • Mylan Specialty L.P. $102
$102 — —
NUCALA
  • GlaxoSmithKline, LLC. $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

197 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record